Related Experiment Videos
Toxicological comments to the discussion about REACH.
Helmut Greim1, Michael Arand, Herman Autrup
1Institute of Toxicology and Environmental Hygiene, Technical University of Munich, Hohenbachernstrasse 15-17, 85350 Freising-Weihenstephan, Germany. helmut.greim@lrz.tum.de
Archives of Toxicology
|January 18, 2006
Summary
European toxicologists argue that waiving animal repeated dose studies under REACH may compromise human and environmental safety. Current in vitro methods lack crucial data for accurate risk assessment, necessitating continued in vivo testing.
Area of Science:
- Toxicology
- Chemical Risk Assessment
- Regulatory Science
Background:
- The European Union's REACH (Registration, Evaluation and Authorization of Chemicals) process aims to identify hazardous substances and assess exposure risks.
- A debate exists regarding the sufficiency of in vitro studies and structure-activity relationships to replace repeated exposure studies in animals.
- Industry and some regulatory bodies advocate for waiving animal studies, prioritizing cost reduction and animal welfare over comprehensive human and environmental protection.
Purpose of the Study:
- To critically evaluate the adequacy of in vitro methods and structure-activity relationships for chemical risk assessment.
- To emphasize the necessity of repeated dose studies in animals for complete hazard identification and risk characterization.
- To address the implications of waiving in vivo studies for human health and environmental safety under the REACH framework.
Main Methods:
- Critical review of existing toxicological data and methodologies.
- Analysis of the limitations of in vitro studies for determining dose-response relationships, thresholds, and No Observed Effect Levels (NOELs).
- Emphasis on the role of repeated dose studies (e.g., 28-day, 90-day) in intact animals for comprehensive hazard identification.
Main Results:
- In vitro studies can identify specific hazardous properties but cannot provide essential data for risk characterization, such as dose-response information and NOELs.
- Repeated dose studies in animals are indispensable for identifying all relevant hazardous properties and endpoints of adverse effects.
- Waiving animal studies leads to incomplete hazard identification, hindering appropriate risk assessment and potentially resulting in unforeseen human exposure effects.
Conclusions:
- The current evidence supporting the replacement of in vivo methods with alternatives for REACH risk assessment is weak.
- Overstating progress in alternative methods may damage their development; more research is needed, but validation is complex and slow.
- Continuing established in vivo methods until properly validated alternatives are available is necessary to ensure adequate human health and environmental protection.